Zürcher Nachrichten - Trump’s Crackdown: Lives/Risk

EUR -
AED 4.258221
AFN 80.584145
ALL 97.338805
AMD 444.976499
ANG 2.075135
AOA 1063.250317
ARS 1500.384005
AUD 1.776081
AWG 2.089977
AZN 1.970786
BAM 1.946221
BBD 2.342351
BDT 142.117244
BGN 1.955847
BHD 0.437052
BIF 3411.793527
BMD 1.159488
BND 1.490381
BOB 8.044641
BRL 6.480495
BSD 1.160105
BTN 100.479079
BWP 15.637549
BYN 3.796237
BYR 22725.965379
BZD 2.33016
CAD 1.592209
CDF 3349.760574
CHF 0.930918
CLF 0.028346
CLP 1112.018613
CNY 8.322631
CNH 8.32342
COP 4841.256749
CRC 585.965357
CUC 1.159488
CUP 30.726433
CVE 109.166008
CZK 24.589209
DJF 206.064608
DKK 7.462894
DOP 70.439103
DZD 150.600003
EGP 56.571071
ERN 17.39232
ETB 159.78337
FJD 2.610933
FKP 0.858002
GBP 0.868167
GEL 3.137536
GGP 0.858002
GHS 12.116065
GIP 0.858002
GMD 83.483255
GNF 10036.528213
GTQ 8.90341
GYD 242.69245
HKD 9.101761
HNL 30.552794
HRK 7.533079
HTG 151.761906
HUF 397.345531
IDR 18998.617185
ILS 3.884581
IMP 0.858002
INR 100.595036
IQD 1518.929319
IRR 48828.941265
ISK 142.199332
JEP 0.858002
JMD 186.095647
JOD 0.822069
JPY 172.001354
KES 150.147816
KGS 101.228083
KHR 4661.141521
KMF 492.20816
KPW 1043.538917
KRW 1612.859572
KWD 0.354142
KYD 0.96665
KZT 630.689528
LAK 25010.156368
LBP 103832.152726
LKR 350.206091
LRD 233.057389
LSL 20.766102
LTL 3.423667
LVL 0.701363
LYD 6.272483
MAD 10.502071
MDL 19.545941
MGA 5136.531239
MKD 61.585922
MMK 2434.434818
MNT 4159.955593
MOP 9.379627
MRU 46.171044
MUR 52.617802
MVR 17.855706
MWK 2013.45107
MXN 21.76347
MYR 4.909854
MZN 74.161141
NAD 20.766677
NGN 1772.857271
NIO 42.610819
NOK 11.81945
NPR 160.766924
NZD 1.940646
OMR 0.44582
PAB 1.159981
PEN 4.225754
PGK 4.808979
PHP 66.350561
PKR 328.193546
PLN 4.260014
PYG 8689.231823
QAR 4.221406
RON 5.072181
RSD 117.148827
RUB 94.324833
RWF 1669.662763
SAR 4.349424
SBD 9.606469
SCR 16.401467
SDG 696.241966
SEK 11.146819
SGD 1.490991
SHP 0.911176
SLE 26.668566
SLL 24313.888811
SOS 662.635838
SRD 42.390274
STD 23999.061214
STN 24.818841
SVC 10.151037
SYP 15075.433439
SZL 20.767055
THB 37.618412
TJS 11.049064
TMT 4.069803
TND 3.327788
TOP 2.715638
TRY 47.030805
TTD 7.888594
TWD 34.411869
TZS 2979.884582
UAH 48.520303
UGX 4158.496123
USD 1.159488
UYU 46.493965
UZS 14609.548786
VES 141.378985
VND 30409.312806
VUV 137.512455
WST 3.17582
XAF 652.682593
XAG 0.030385
XAU 0.00035
XCD 3.133574
XCG 2.090657
XDR 0.804
XOF 648.153562
XPF 119.331742
YER 279.291697
ZAR 20.755645
ZMK 10436.779943
ZMW 27.201534
ZWL 373.354672
  • RBGPF

    3.6700

    77.55

    +4.73%

  • SCU

    0.0000

    12.72

    0%

  • CMSD

    0.0100

    22.9

    +0.04%

  • SCS

    0.2700

    10.85

    +2.49%

  • CMSC

    0.0150

    22.5

    +0.07%

  • RIO

    -0.9100

    62.19

    -1.46%

  • NGG

    -1.8300

    70.32

    -2.6%

  • BTI

    -0.4700

    51.78

    -0.91%

  • GSK

    -0.5200

    37.45

    -1.39%

  • RELX

    -0.9600

    51.77

    -1.85%

  • BCC

    -1.4000

    86.74

    -1.61%

  • BP

    0.4700

    32.67

    +1.44%

  • BCE

    -0.3700

    23.83

    -1.55%

  • JRI

    -0.0600

    13.03

    -0.46%

  • RYCEF

    -0.0500

    13.15

    -0.38%

  • VOD

    -0.2700

    11.16

    -2.42%

  • AZN

    -0.8300

    71.83

    -1.16%


Trump’s Crackdown: Lives/Risk




In a dramatic push to tackle the skyrocketing cost of prescription drugs in the United States, President Donald Trump has taken decisive action against the pharmaceutical industry. With the stroke of a pen, he signed an executive order designed to slash drug prices, promising relief for millions of Americans burdened by exorbitant healthcare costs. However, this bold move has sparked fierce debate, with critics warning that the consequences could be catastrophic—potentially costing millions of lives due to drug shortages and stifled innovation.

Trump’s Plan to Lower Drug Prices
The executive order, enacted on May 12, 2025, seeks to align U.S. drug prices with those in other developed nations, where medications often cost a fraction of what Americans pay. Trump has long criticized the pharmaceutical industry for what he calls unfair pricing practices, arguing that U.S. consumers have been overcharged for years. The order aims to reduce prices by 30% to 80%, targeting both brand-name and generic drugs. It relies on voluntary compliance from drug companies, with the threat of future regulations looming if they fail to cooperate. For many patients, this could mean significant savings on medications that currently drain their finances.

The Dark Side: Drug Shortages Loom
While the goal of affordability is laudable, the plan has raised red flags among healthcare experts and industry leaders. One major concern is the risk of drug shortages. The U.S. already faces periodic shortages of critical medications, such as those used in cancer treatments and epidurals. Forcing pharmaceutical companies to lower prices could make it unprofitable to produce certain drugs, particularly low-cost generics. If production slows or stops, hospitals and pharmacies could struggle to secure enough supply, leaving patients without access to life-saving treatments. The ripple effect could be devastating, especially for vulnerable populations like cancer patients and the elderly.

A Blow to Innovation
Beyond immediate supply issues, the executive order could deal a severe blow to pharmaceutical innovation. Developing new drugs is an expensive and risky endeavor, often costing billions of dollars and taking years of research. The U.S. market, with its higher drug prices, has long been a key source of revenue for this work. If that revenue shrinks, companies may cut back on research and development, slowing the creation of new treatments for diseases like Alzheimer’s, cancer, and rare genetic disorders. A healthcare economist recently cautioned that such a move could “delay breakthroughs that millions of patients are counting on,” trading short-term savings for long-term losses in medical progress.

Economic Fallout
The economic implications are equally troubling. The pharmaceutical industry employs thousands of Americans and drives significant investment in the U.S. economy. Lower prices could lead to job cuts and reduced funding for new projects. One major drug company has already hinted at rethinking its $50 billion investment in the U.S. if the order takes full effect. While consumers might save money at the pharmacy, the broader economy could suffer as a result.

The Case for Change
Despite these risks, supporters argue that action is overdue. Prescription drug prices in the U.S. are nearly three times higher than in other advanced countries, forcing many Americans to ration their medications or skip doses entirely. Lowering prices could save billions of dollars and improve access for those with chronic conditions like diabetes or heart disease. For these patients, Trump’s order represents a lifeline—a chance to afford the drugs they need to survive.

A High-Stakes Gamble
As the dust settles, the debate rages on. Will Trump’s crackdown on the pharmaceutical industry deliver on its promise of affordable healthcare, or will it unleash a cascade of unintended consequences? The order’s success hinges on cooperation from an industry reluctant to sacrifice profits, and its failure could leave patients paying the ultimate price. For now, the nation watches as this high-stakes gamble unfolds, with millions of lives in the balance.